TORONTO and AACHEN, Germany, Feb. 5, 2026 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, ...
Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...
AACHEN, Germany, July 14, 2022 /PRNewswire/ -- Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire Nebido TM, the ...
German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation. Bayer and ...
AACHEN, Germany and TORONTO, Feb. 5, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical ...
BERLIN - Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. The deal, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results